Rogue

ROGUE (Rx On-site Generation Using Electronics) is a biotechnology company developing a 'living pharmacy' platform designed to produce biologic medicines on demand within the human body. The core technology consists of a durable, minimally invasive implantable device containing engineered cells that synthesize and release therapeutic proteins in response to electronic signals. Its lead application targets obesity and type 2 diabetes by producing glucagon-like peptide 1 receptor agonists (GLP-1 RAs), potentially replacing frequent injections with a long-term, self-regulating solution. The company aims to drastically lower the cost of biologics and improve patient adherence through real-time, closed-loop bioelectronic monitoring and dosing.